Vol. 30 No. 119 (2022), Original publication
Vol. 30 No. 119 (2022)

Leukocyte and Platelet-Rich Fibrin (LPRF) Therapy & Leprosy:: the Need for Caution and Research Among Marginalised Groups in Low Resource Settings

Original publication
Published 2023-03-15
Frank Houghton
Limerick Institute of Technology image/svg+xml
Margaret Moran Stritch
University Hospital Limerick image/svg+xml
Krishna Tamang
Lalgadh Leprosy Hospital & Services Centre
Michael Winterburn
Technological University of the Shannon
PDF

Keywords

LPRF; Leukocyte and Platelet-Rich Fibrin Therapy; Leprosy; Nepal; Resistance

How to Cite

1.
Leukocyte and Platelet-Rich Fibrin (LPRF) Therapy & Leprosy:: the Need for Caution and Research Among Marginalised Groups in Low Resource Settings. MIR [Internet]. 2023 Mar. 15 [cited 2026 Feb. 9];30(119):86-91. Available from: https://interrev.com/mir/index.php/mir/article/view/207
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Abstract

This paper discusses the potential of Leukocyte and Platelet-Rich Fibrin Therapy (LPRF) to help treat ulcers and skin damage associated with leprosy. It warns that although LPRF may be a valuable and cost-effective treatment, it is crucial to understand potential resistance to haematologically based treatments. For physicians and health service staff operating within a biomedical paradigm, folk beliefs resisting such treatments may be inconsequential. However, research and education among marginalised and excluded populations is vital to overcome potential hesitancy and resistance to such treatments.

PDF